Pages that link to "Q37360526"
Jump to navigation
Jump to search
The following pages link to Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. (Q37360526):
Displaying 50 items.
- TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu (Q21131200) (← links)
- Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes (Q24674180) (← links)
- Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy (Q24814910) (← links)
- A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens (Q27023313) (← links)
- Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection (Q27680531) (← links)
- H2-Mbeta 1 and H2-Mbeta 2 heterodimers equally promote clip removal in I-A(q) molecules from autoimmune-prone DBA/1 mice (Q28585977) (← links)
- Vaccination for melanoma (Q30306588) (← links)
- TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis (Q32159956) (← links)
- High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients (Q33432819) (← links)
- Cancer vaccines: novel approaches and new promise (Q33586656) (← links)
- Impaired cell surface expression of HLA-B antigens on mesenchymal stem cells and muscle cell progenitors (Q33598281) (← links)
- Cancer gene and immunotherapy: recent developments (Q33717186) (← links)
- Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy (Q33732738) (← links)
- T-cell recognition of melanoma-associated antigens (Q33827458) (← links)
- Immunology and immunotherapy of human cancer: present concepts and clinical developments (Q33899097) (← links)
- Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy (Q33911899) (← links)
- CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate. (Q33931006) (← links)
- Immune selection in neoplasia: towards a microevolutionary model of cancer development (Q33948688) (← links)
- Antigen-processing machinery breakdown and tumor growth (Q34011098) (← links)
- Development of non-live vectors and procedures (liposomes, pseudo-viral particles, toxin, beads, adjuvantsellipsis) as tools for cancer vaccines. (Q34038768) (← links)
- Strategies to overcome obstacles to successful immunotherapy of melanoma (Q34042968) (← links)
- Trends in cancer immunotherapy (Q34052702) (← links)
- Melanoma peptide vaccines: from preclinical background to clinical trials (Q34107773) (← links)
- Immunotherapy of metastasis. (Q34267670) (← links)
- Regulation of tumor growth by IFN-gamma in cancer immunotherapy. (Q34397096) (← links)
- Modeling putative therapeutic implications of exosome exchange between tumor and immune cells (Q34407541) (← links)
- Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells (Q34415738) (← links)
- T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance (Q34452013) (← links)
- Peptide vaccines for cancer (Q34568992) (← links)
- Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction (Q35005940) (← links)
- Synthetic and natural non-live vectors: rationale for their clinical development in cancer vaccine protocols (Q35023514) (← links)
- Therapeutic vaccination with tumor cells that engage CD137. (Q35071688) (← links)
- CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation (Q35228053) (← links)
- IFNγ producing CD8(+) T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas (Q35507485) (← links)
- Cell surface expression level variation between two common Human Leukocyte Antigen alleles, HLA-A2 and HLA-B8, is dependent on the structure of the C terminal part of the alpha 2 and the alpha 3 domains (Q35741278) (← links)
- Challenges and future perspectives of T cell immunotherapy in cancer (Q35843507) (← links)
- Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma (Q35886748) (← links)
- Regulators of apoptosis: suitable targets for immune therapy of cancer (Q36111911) (← links)
- Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth (Q36476449) (← links)
- Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression (Q36509702) (← links)
- Vaccination: role in metastatic melanoma. (Q36573868) (← links)
- Vaccine therapy for melanoma: current status and future directions (Q36889580) (← links)
- Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies (Q37047061) (← links)
- HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses (Q37066149) (← links)
- Specificity in cancer immunotherapy (Q37236636) (← links)
- Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma (Q37328301) (← links)
- Multipeptide vaccination in cancer patients. (Q37547268) (← links)
- Improving T cell responses to modified peptides in tumor vaccines (Q37634253) (← links)
- Influence of immune privilege on ocular tumor development (Q37724789) (← links)
- The role of antigen-specific and non-specific immunotherapy in the treatment of cancer (Q38021845) (← links)